

Resource Summary Report

Generated by [dkNET](#) on Aug 25, 2026

Phospho-LAT (Tyr171) Antibody

RRID:AB_2157730

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 3581, RRID:AB_2157730

Antibody Information

URL: http://antibodyregistry.org/AB_2157730

Proper Citation: Cell Signaling Technology Cat# 3581, RRID:AB_2157730

Target Antigen: LAT, phospho (Tyr171)

Clonality: unknown

Comments: Applications: W

Antibody Name: Phospho-LAT (Tyr171) Antibody

Description: This unknown targets LAT, phospho (Tyr171)

Target Organism: mouse, human

Antibody ID: AB_2157730

Vendor: Cell Signaling Technology

Catalog Number: 3581

Record Creation Time: 20250820T042053+0000

Record Last Update: 20250820T184334+0000

Ratings and Alerts

No rating or validation information has been found for Phospho-LAT (Tyr171) Antibody.

No alerts have been found for Phospho-LAT (Tyr171) Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Rainwater RR, et al. (2026) DNA-PKcs controls the cytotoxic T cell response to cancer and transplant allograft through regulating LAT-dependent signaling. Cell reports, 45(1), 116796.

Pham-Danis C, et al. (2025) Restoration of LAT activity improves CAR T cell sensitivity and persistence in response to antigen-low acute lymphoblastic leukemia. Cancer cell, 43(3), 482.

Funasaki S, et al. (2023) A stepwise and digital pattern of RSK phosphorylation determines the outcome of thymic selection. iScience, 26(9), 107552.

Palmer DC, et al. (2022) Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade. Med (New York, N.Y.), 3(10), 682.

Guha J, et al. (2021) Disc Large Homolog 1 Is Critical for Early T Cell Receptor Micro Cluster Formation and Activation in Human T Cells. Vaccines, 9(12).

Celis-Gutierrez J, et al. (2019) Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy. Cell reports, 27(11), 3315.